Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806)

Size: px
Start display at page:

Download "Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806)"

Transcription

1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806) Presented by: Cap Uldriks, FDA Daniel P. Olivier, CCS Page 1

2 Objectives Define regulatory reporting rules based on on established standards Simplify regulatory reporting decision making Establish defensible basis to to support compliance with with reporting regulations Reduce risk risk of of non-compliance observations Page 2

3 AGENDA Reporting Regulations Evaluating Safety Risks Defining the Strategy Summary Page 3

4 Reporting + Regulations Page 4

5 21 21 CFR Part 803: Medical Device Reporting MDR reportable event means: (1) User facilities become aware of information that reasonably suggests a device has or may have caused or contributed to a death or serious injury; or (2) Manufacturers or importers become aware of information that reasonably suggests one of their marketed devices: (i) May have caused or contributed to a death or serious injury, or (ii) Has malfunctioned and that the device or a similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. Page 5

6 Compliance Program Guidance for CFR Part 803: Medical Device Reporting If the event is likely to cause or contribute to death or serious injury" then the event is reportable The preamble offers the following guidance, i.e., a malfunction report is required when: 1.The chance of a death or serious injury occurring as a result of the recurrence of the malfunction is not remote 2.The consequences of the malfunction affect the device in a catastrophic manner that may lead to a death or serious injury (Class I Recall) Page 6

7 21 21 CFR Part 806: Corrections and Removal Reporting Sec Reports of corrections and removals. (a) Each device manufacturer or importer shall submit a written report to FDA of any correction or removal of a device initiated by them: (1) To reduce a risk to health posed by the device; or (2) To remedy a violation of the act caused by the device which may present a risk to health unless the information has already been provided under Part 803 or Part 1004 or the action is exempt from the reporting under 806.1(b). Page 7

8 Compliance Program Guidance for CFR Part 806: FDA Corrections and Removals Reporting Risk to Health - The key concept to determine whether an event is reportable under Part 806: Use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or an outcome where the probability of serious adverse health consequences is remote (Class II Recall). Page 8

9 21 21 CFR Part 7.3: Recall Class Definitions Class I is a situation in which there is reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death (criteria for 803 reporting) Class II is a situation in which there is reasonable probability that the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote (criteria for 806 reporting) Class III is a situation in which there is reasonable probability that the use of, or exposure to, a violative product is not likely to cause serious adverse health consequences Page 9

10 Evaluating + Safety Risk Page 10

11 Risk Evaluation, Severity Severity* - Assess the worst possible consequence, defined by degree of injury or illness that could occur. Severity classification identified as follows: Major, may cause death or serious injury Moderate, may cause non-serious injury Minor, not expected to cause injury *Based on Levels of Concern defined in Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, Food and Drug Administration, May 11,2005. Page 11

12 MIL-STD 882D* Severity Levels Severity: Suggested mishap categories: Catastrophic, could result in death, permanent total disability, loss exceeding $1M Critical, could result in permanent partial disability, or that may result in hospitalization of at least three people, $200k-$1M loss Marginal, could result in injury resulting in more than one lost work day, $10K-$200K loss Negligible, could result in injury resulting in less than one lost day, less than $10K * Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, 2000, Appendix A, Table A-1, page 18 Page 12

13 ISO 14971:2000* Severity Levels Severity: levels may be descriptive, e.g. Catastrophic Serious Critical Marginal Negligible * Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000 section E.2.2, page 32 Page 13

14 Consolidated Severity Levels MIL-STD 882D ISO 14971:2000 FDA Guidance Catastrophic Catastrophic Major Serious Major Critical Critical Major Marginal Marginal Moderate Negligible Negligible Minor Page 14

15 MIL-STD-882D* Risk Evaluation, Probability Probability* - Probability that a mishap will occur during the planned life expectancy of the system: Frequent - Likely to occur often (X > 10-1 ) Probable - Will occur several times in the life of the system. (10-1 >X >10-2 ) Occasional - Likely to occur sometime in the life of the system. (10-2 >X >10-3 ) Remote - Unlikely but possible to occur in the life of the system. (10-3 >X >10-6 ) Improbable - So unlikely, it can be assumed occurrence may not be experienced (X < 10-6 ) * Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, 2000, Appendix A, Table A-2, page 19 Page 15

16 ISO 14971:2000* Risk Evaluation, Probability Probability - Probability estimation examines the initiating events or circumstances and the sequences of events that are of concern: Frequent Probable Occasional Remote Improbable Incredible * Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000 section E.2.1, page 31 Page 16

17 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Probable Occasional Remote Improbable Minor Moderate Major Note: Probability level of Incredible from ISO 14971:2003 not included Page 17

18 Defining the Strategy Page 18

19 Compliance Program Guidance for CFR Part 803: Medical Device Reporting If the event is likely to cause or contribute to death or serious injury" then the event is reportable The preamble offers the following guidance, i.e., a malfunction report is required when: 1.The chance of a death or serious injury occurring as a result of the recurrence of the malfunction is not remote; 2.The consequences of the malfunction affect the device in a catastrophic manner that may lead to a death or serious injury Page 19

20 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Probable Occasional Remote Improbable Minor Moderate Major MDR MDR MDR Note: Probability level of Incredible from ISO 14971:2003 not included Page 20

21 Compliance Program Guidance for CFR Part 806: FDA Corrections and Removals Reporting Reports are NOT required IF: The information has already been reported to FDA under the MDR regulation, 21 CFR Part 803 or under 21 CFR 1004 (Replacement of Electronic Products). The key concept for determining when an event is reportable is the CAR regulation's definition of risk to health: Use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or an outcome where the probability of serious adverse health consequences is remote (Class II Recall). Page 21

22 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Minor Moderate NR CAR Major MDR Probable NR CAR MDR Occasional NR CAR MDR Remote NR NR CAR Improbable NR NR NR NR - Not reportable CAR - Reportable under 21 CFR Part 806 MDR - reportable under 21 CFR Part 803 Page 22

23 Summary Page 23

24 Defining Reporting Strategy Reference to external standards/guidelines provides defensibility for decision making Established rules provide: consistency use of common terminology facilitate training Established rules reduce compliance risk Page 24

25 References Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000. Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, FDA, Office of Device Evaluation, May 11, Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, CFR Part 7 Enforcement Policy, US Federal Register, Food and Drug Administration. Page 25

AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide

AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide AFDO Conference June 9, 2009 Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide Government Agencies 483 observations A violation of the FD&C Act involving

More information

FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions

FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions 23 January 2017 On December 27, 2016, the U.S. Food and Drug

More information

BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018

BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018 BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE Yuan Xu 18- JAN- 2018 Background AGENDA What is Medical Device? What is 510(k)? Principles of best practices of device

More information

Using Recall Data to Assess the 510(k) Process

Using Recall Data to Assess the 510(k) Process Using Recall Data to Assess the 510(k) Process Ralph F. Hall Distinguished Professor and Practitioner University of Minnesota Law School July 28, 2010 Acknowledgments 2 Disclosures 3 Agenda I. Research

More information

2/17/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

2/17/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)

More information

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)

More information

Preparing a US FDA Medical Device 510(K) Submission

Preparing a US FDA Medical Device 510(K) Submission Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via

More information

TOBACCO PRODUCT OR MEDICAL PRODUCT?

TOBACCO PRODUCT OR MEDICAL PRODUCT? TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:

More information

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 4. Intro ISO GMP - GLP Pierre-Alain Sommer

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 4. Intro ISO GMP - GLP Pierre-Alain Sommer Nano-Tera.ch 05 February 2015 part 4 Intro ISO GMP - GLP Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 Introduction to ISO 13485, cgmp s and GLP s Context

More information

Residual Solvents: FDA/ Regulatory Perspective

Residual Solvents: FDA/ Regulatory Perspective Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements

More information

September 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

September 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 September 28, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. : Center for Devices and Radiological Health 510(k)

More information

510(k) submissions. Getting US FDA clearance for your device: Improving

510(k) submissions. Getting US FDA clearance for your device: Improving Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white

More information

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers

More information

DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS

DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS Page 1 of 6 Human Research Protection Page: 1 of 6 DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS DESCRIPTION Any proposed activity involving contact with

More information

Draft Guidance for Industry and FDA Staff

Draft Guidance for Industry and FDA Staff Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document

More information

Overview of the Legal Framework for Medical Device Regulation in the United States

Overview of the Legal Framework for Medical Device Regulation in the United States 1 Overview of the Legal Framework for Medical Device Regulation in the United States Ellen J. Flannery This chapter provides an overview of the legal framework for medical device regulation in the United

More information

Raritan Pharmaceuticals, Inc. 6/20/17

Raritan Pharmaceuticals, Inc. 6/20/17 Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,

More information

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule

More information

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments

More information

(Cochineal Extract and Carmine: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain These Color Additives)

(Cochineal Extract and Carmine: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain These Color Additives) ก ก 2553 ก : ก (Cochineal Extract and Carmine: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain These Color Additives) : ก ก ก : ก ก ก : 2552 : 2552 1 ก 5 ก : ก (Cochineal

More information

Agency Information Collection Activities; Submission for Office of Management and Budget

Agency Information Collection Activities; Submission for Office of Management and Budget This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

FDA 510(k) 101 The Basics

FDA 510(k) 101 The Basics FDA 510(k) 101 The Basics Floyd G. Larson President, PaxMed International San Diego, CA OMTEC June 17, 2010 Chicago Agenda History of 510(k) process FDA s risk based approach FDA guidance and standards

More information

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update

More information

Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/

Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/ Department of Health and Human Services Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Telephone: 510/337-6700 WARNING LETTER December

More information

Premarket Notification: Analysis of FDA Recall Data

Premarket Notification: Analysis of FDA Recall Data Premarket Notification: Analysis of FDA Recall Data Director, Medical Device Safety Institute Beth Israel Deaconess Medical Center Boston, MA IOM 510(k) Workshop July 28, 2010 Disclosure FDA Consultant

More information

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 January 2010 Version 2.0 Table of Contents 1. INTRODUCTION...1 1.1 Scope... 1 1.2 Purpose... 1 1.3 Responsibilities...

More information

2014 FDA/JIFSAN Food & Nutrition Webinar

2014 FDA/JIFSAN Food & Nutrition Webinar 2014 FDA/JIFSAN Food & Nutrition Webinar Medical Foods Shawne Suggs-Anderson, MMSc, _ RD Infant Formula and Medical Foods Staff ONLDS/CFSAN/FDA September 23, 2014 53 Main Objectives History What is a Medical

More information

Agency Information Collection Activities; Submission for Office of Management and

Agency Information Collection Activities; Submission for Office of Management and This document is scheduled to be published in the Federal Register on 03/04/2019 and available online at https://federalregister.gov/d/2019-03824, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

Agency Information Collection Activities; Submission for Office of Management and

Agency Information Collection Activities; Submission for Office of Management and This document is scheduled to be published in the Federal Register on 02/19/2019 and available online at https://federalregister.gov/d/2019-02596, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

Use of Standards in Substantial Equivalence Determinations

Use of Standards in Substantial Equivalence Determinations Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration

More information

Hieber's Pharmacy 12/5/17

Hieber's Pharmacy 12/5/17 Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED

More information

LIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement

LIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Food Recall Process Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement Wednesday, December 9, 2009 LEGAL ISSUES Code of Federal Regulations

More information

General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff

General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff Document issued on: July 29, 2016. The draft of this document was issued on January 20, 2015.

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN

More information

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK Federal, State and AABB requirements for nonconforming product investigation and recipient look back for adverse impact Stacy Ralston MPH, CLS (ASCP), RAC

More information

NRMP Reporting Requirements

NRMP Reporting Requirements NRMP ing s (s will be made to NAVENVIRHLTHCEN Medical (1) (i) The total dose delivered differs from the prescribed dose by 20 percent or more; (ii) The total dosage delivered differs from the prescribed

More information

Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food

Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food http://www.fda.gov/fsma THE FUTURE IS NOW 1 Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive

More information

40 CFR PART DENTAL OFFICE POINT SOURCE CATEGORY

40 CFR PART DENTAL OFFICE POINT SOURCE CATEGORY 40 CFR PART 441 - DENTAL OFFICE POINT SOURCE CATEGORY 441.10 Applicability. (a) Except as provided in paragraphs (c), (d), and (e) of this section, this part applies to dental dischargers. (b) Unless otherwise

More information

Town and Country Compounding and Consultation Services, LLC 10/17/17

Town and Country Compounding and Consultation Services, LLC 10/17/17 Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 9 Inspections, Compliance, Enforcement, and Criminal Investigations Phoenix Medical Devices, LLC 9/29/2009 Department of Health and Human Services Public Health Service Food and Drug Administration

More information

SAMED Position: Reuse of SUDs

SAMED Position: Reuse of SUDs SAMED Position: Reuse of SUDs What We Will Cover SAMED - who we are and what we do Definition of single-use device Overview of single-use device reprocessing Overview of SA and other countries regulatory

More information

In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review

In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review Cardiac Safety Research Consortium December 3, 2015 Lea Carrington Division of Immunology and Hematology Devices Office of In

More information

Standards of Conduct for Transmission Providers

Standards of Conduct for Transmission Providers Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission

More information

Compliance with the Dental Rule in Virginia

Compliance with the Dental Rule in Virginia Compliance with the Dental Rule in Virginia Industrial Waste and Pretreatment Conference Charlottesville, VA March 6 th, 2018 Deborah DeBiasi, DEQ Deborah.DeBiasi@deq.Virginia.gov 804-698-4028 Purpose

More information

Border Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas

Border Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas Border Issues and Statistics: Regulatory Activities Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas U.S. Food & Drug Administration Mission Statement The Food & Drug Administration

More information

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Research That Must Be Reviewed by the IRB

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Research That Must Be Reviewed by the IRB Page: 1 of 5 I. PURPOSE II. III. IV. To provide guidance on the types of research activities that are subject to review and approval by the Committees for the Protection of Human, which comprise the Institutional

More information

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Donald Kautter US Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food

More information

FDA Basics FDA s Import Operations: How FDA Regulates Imported Products

FDA Basics FDA s Import Operations: How FDA Regulates Imported Products FDA Basics FDA s Import Operations: How FDA Regulates Imported Products Carlos W. Hernandez Compliance Officer U.S. Food and Drug Administration Global Regulatory Operations and Policy Office of Regulatory

More information

Stonegate Pharmacy LP 11/10/16

Stonegate Pharmacy LP 11/10/16 Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite

More information

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. Preface

U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. Preface U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Preface Public Comment: The Food and Drug Administration (FDA) is announcing the availability

More information

Key CDRH Regulatory Initiatives

Key CDRH Regulatory Initiatives Key CDRH Regulatory Initiatives Revamping the Submission Process Creating New Strategies Ralph F. Hall University of Minnesota Law School Counsel Faegre Baker & Daniels May 8, 2012 Purpose of Today s Program

More information

Medical Device Approval and Product Recalls

Medical Device Approval and Product Recalls Medical Device Approval and Product Recalls Presented by Sean P. Farley, MBA, CMRP Director, Organizational Procurement Virginia Mason Medical Center President, WSHMMA - Introduction and the Business Environment

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

Family Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents

Family Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents Family Smoking Prevention and Tobacco Control Act (PUBLIC LAW 111-31 JUNE 22, 2009) Comments regarding crop protection agents Presentation Objectives What is the intent of FDA in regulating CPAs? What

More information

SFIREG Issue Paper: Pesticide Use on Cannabis State Established Pesticide Residue Action Levels

SFIREG Issue Paper: Pesticide Use on Cannabis State Established Pesticide Residue Action Levels SFIREG Issue Paper: Pesticide Use on Cannabis State Established Pesticide Residue Action Levels Introduction to Issue: In recent years, with the approval of medical and recreational use of marijuana in

More information

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance

More information

ContiTech North America

ContiTech North America ContiTech North America Dear Customer: Certain products now contain the following warning language about certain chemicals or compounds that may be found in Continental ContiTech s products or component

More information

QA Regulatory forum: Classification and Risk assessment according to MDR Date : T h e r e s e. A l b i n s s o m e d q t e c h.

QA Regulatory forum: Classification and Risk assessment according to MDR Date : T h e r e s e. A l b i n s s o m e d q t e c h. QA Regulatory forum: Classification and Risk assessment according to MDR Date : 05.04.2018 THERESE ALBINSSON T h e r e s e. A l b i n s s o n @ m e d q t e c h. s e MedQtech AB MedQtech AB is a consultant

More information

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch Libia Lugo Drug Specialist San Juan District Office Investigations Branch The Food and Drug Administration (FDA) responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico,

More information

510(k) 21 Summary of Safety and Effectiveness

510(k) 21 Summary of Safety and Effectiveness 510(k) 21 Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirement of 21 CFR 807.92. Submitter's Identification:

More information

Guidance for the Network Review of Chemotherapy Errors

Guidance for the Network Review of Chemotherapy Errors Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table

More information

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE ISSUED BY: Research PAGE: 1 of 6 REPLACES POLICY DATED: EFFECTIVE DATE: 08/09/2012 DISTRIBUTION: Departmentwide APPROVED BY: Andrews, April (SVP/CECO), BOD Audit and Compliance Committee, Perdomo, Jose

More information

PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES

PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 040-1 3 Appendices 1 January 2019 PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PIC/S January 2019 Reproduction

More information

July 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342

July 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service July 10, 2015 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 X-spine

More information

ATTACHMENT A AdvaMed Comments Draft-Guidance for Industry and FDA Staff -510(k) Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device Line(s) No. Line or lines numbers of the

More information

Informational Memo. Communication Assistance Compliance Standards for Individuals who are Deaf. ODP Communication Number: Memo

Informational Memo. Communication Assistance Compliance Standards for Individuals who are Deaf. ODP Communication Number: Memo Informational Memo Communication Assistance Compliance Standards for Individuals who are Deaf ODP Communication Number: Memo 018-15 The mission of the Office of Developmental Programs is to support Pennsylvanians

More information

COMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019

COMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019 COMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019 HISTORY The Common Rule has been in effect since 1991, and was adopted by 15 federal departments and agencies, including the Department of Health

More information

Shawn Stevens Food Industry Consultant and Lawyer

Shawn Stevens Food Industry Consultant and Lawyer Shawn Stevens Food Industry Consultant and Lawyer stevens@foodindustrycounsel.com 920.698.2561 COMPLYING WITH FSMA S PREVENTIVE CONTROL RULE AS A SMALL BUSINESS COMPLYING WITH FSMA S PREVENTIVE CONTROL

More information

Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA

Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the

More information

Checklist of issues to be considered by food business operators when implementing Commission Regulation (EC) No 2073/2005

Checklist of issues to be considered by food business operators when implementing Commission Regulation (EC) No 2073/2005 Checklist of issues to be considered by food business operators when implementing Commission Regulation 1. General requirements 2. Sampling foodstuffs and testing against the relevant criteria 2.1 Validation

More information

DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J

DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J JON S. CORZINE Governor DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J. 08625-0360 www.nj.gov/health HEATHER HOWARD Commissioner TO: FROM: Public Health Council Heather Howard Commissioner

More information

GOOD REGULATORY REVIEW PRACTICES WORKING GROUP UPDATE. Working Group Chair: Melissa Torres US Food and Drug Administration

GOOD REGULATORY REVIEW PRACTICES WORKING GROUP UPDATE. Working Group Chair: Melissa Torres US Food and Drug Administration GOOD REGULATORY REVIEW PRACTICES WORKING GROUP UPDATE Working Group Chair: Melissa Torres US Food and Drug Administration GOALS The Good Regulatory Review Practices working group has focused efforts on

More information

Food Additives Program

Food Additives Program U.S. FDA s Food Additive Program: An Update on Resources and Challenges 18 th Food Packaging Law Seminar October 11, 2017 Arlington, VA 1 Food Additives Program Dennis Keefe, PhD Director, Office of Food

More information

Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA.

Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA. Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA (Laser Notice 51) Document issued on: May 27, 2001 U.S. Department of Health

More information

Primer: Medical Device User Fee Amendments Han Zhong l September 2011

Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration

More information

Inter-Agency Overlap and Jurisdictional Boundaries

Inter-Agency Overlap and Jurisdictional Boundaries Inter-Agency Overlap and Jurisdictional Boundaries FDLI Food Advertising, Labeling, and Litigation Conference September 14, 2017 Jessica P. O Connell Covington & Burling LLP jpoconnell@cov.com 1 FDA Approach/Perspective

More information

THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE

THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE An overview by Sarah Vugigi, M. Pharm, Elys Chemical Industries Ltd, Nairobi, Kenya INTRODUCTION This guidance describes

More information

CDRH: 510(k)S AND SCIENCE IN REGULATOR DECISION-MAKING. lannery, Scott Danzis and Christopher Pruitt. November 2010 SPECIAL REPRINT

CDRH: 510(k)S AND SCIENCE IN REGULATOR DECISION-MAKING. lannery, Scott Danzis and Christopher Pruitt. November 2010 SPECIAL REPRINT November 2010 SPECIAL REPRINT CDRH: 510(k)S AND SCIENCE IN REGULATOR ORY DECISION-MAKING By Ellen Flanner lannery, Scott Danzis and Christopher Pruitt Reproduced with the kind permission of Global Regulatory

More information

FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC

FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC AIPLA Annual Meeting Joint Biotechnology Committee/ Special Committee on FDA Law Program October 21, 2010 Marriott Wardman Park Hotel Washington, DC FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs

More information

Eyewash and Safety Showers HM 20 Page 1

Eyewash and Safety Showers HM 20 Page 1 Policy Subject: Safety Showers and Eyewash Effective: 12/01/09 Stations Affected Area/Department: University of Tennessee Reviewed/Revised: 12/15/08 Policy It shall be the policy of the University of Tennessee

More information

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and

More information

PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001

PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001 PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS LCB File No. R062-01 July 6, 2001 EXPLANATION Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY:

More information

CITY OF PALMER, ALASKA. Ordinance No

CITY OF PALMER, ALASKA. Ordinance No Initiative Petition Submitted to City Clerk: July 3, 2012 Petition Certified by City Clerk: July 6, 2012 Measure Placed Before the Voters at the Regular Election of: October 2, 2012 Proposition No. 3,

More information

CERTIFICATE OF ANALYSIS. tel: fax:

CERTIFICATE OF ANALYSIS. tel: fax: CERTIFICATE OF ANALYSIS 300 Technology Drive Christiansburg, VA 24073. USA inorganicventures.com tel: 800.669.6799. 540.585.3030 fax: 540.585.3012 info@inorganicventures.com 1.0 ACCREDITATION / REGISTRATION

More information

Dear Valued Customer,

Dear Valued Customer, Dear Valued Customer, As part of our mission to return clean water to our environment, the Washington Suburban Sanitary Commission's (WSSC) Industrial Discharge Control Program is responsible for monitoring

More information

IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK

IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK Dr Alison Beaney Regional QA Specialist NE and N Cumbira IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE

More information

TGA: the current regulatory reform agenda

TGA: the current regulatory reform agenda TGA: the current regulatory reform agenda ASMI 2012 Conference: 13 November 2012 Future proofing the consumer healthcare industry Dr John Skerritt, National Manager The Therapeutic Goods Administration

More information

Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food

Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Lillian Hsu, Ph. D. 2018 American Hop Convention January 25, 2018 2 Who is Covered by Part 117? In

More information

Guidance - IDE Early/Expanded Access for Devices

Guidance - IDE Early/Expanded Access for Devices Guidance - IDE Early/Expanded Access for Devices An unapproved medical device may normally only be used on human subjects through an approved clinical study in which the subjects meet certain criteria

More information

The Basics of the U.S. FDA s Regulation of Materials Used in Food Packaging Applications

The Basics of the U.S. FDA s Regulation of Materials Used in Food Packaging Applications The Basics of the U.S. FDA s Regulation of Materials Used in Food Packaging Applications RadTech UV & EB Technology Expo & Conference 2012 Presented by David J. Ettinger Partner Keller and Heckman LLP

More information

Al Garcia. CIPCA October 12, 2018

Al Garcia. CIPCA October 12, 2018 Al Garcia CIPCA October 12, 2018 Final 2016 Effluent Limitation Guidelines Plan Published for Public Comment May 2, 2018 https://www.gpo.gov/fdsys/pkg/fr- 2018-05-02/pdf/2018-09320.pdf Final 2016 ELG Plan

More information

Regulatory Update: Food Safety and Nutrition

Regulatory Update: Food Safety and Nutrition Regulatory Update: Food Safety and Nutrition Ricardo Carvajal Hyman, Phelps & McNamara, P.C. www.hpm.com www.fdalawblog.net North American Millers Association March 2015 Today s Agenda FSMA Update Biological

More information

Listing of Color Additives Exempt from Certification; Synthetic Iron Oxide

Listing of Color Additives Exempt from Certification; Synthetic Iron Oxide This document is scheduled to be published in the Federal Register on 03/20/2015 and available online at http://federalregister.gov/a/2015-06418, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

Multi Analyte Custom Grade Solution

Multi Analyte Custom Grade Solution 1.0 ACCREDITATION / REGISTRATION INORGANIC VENTURES is accredited to ISO Guide 34, "General Requirements for the Competence of Reference Material Producers" and ISO/IEC 17025, "General Requirements for

More information

Dental Amalgam Rule Update

Dental Amalgam Rule Update Dental Amalgam Rule Update Pacific Northwest Pretreatment Workshop Vancouver, Washington September 11, 2017 Jay Pimpare EPA New England Regional Pretreatment Coordinator 1 40 CFR 441 Dental Rule Schedule

More information

Talon Compounding Pharmacy 10/3/17

Talon Compounding Pharmacy 10/3/17 Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING

More information

Donald W. Guthner Orgenix, LLC Ill Hill Road. Douglassville, PA (888) ORGENIX ( ) (484) (FAX) Intramedullary Nails, Nails

Donald W. Guthner Orgenix, LLC Ill Hill Road. Douglassville, PA (888) ORGENIX ( ) (484) (FAX) Intramedullary Nails, Nails K070741 ~, SANATMETAL Manufacturer of Orthopaedic and Traumatologic Products H-3301, Eger Faiskola ut 5. Phone: +(36)36-512-900 Fax: +(36)36-512-932 e-mail: metalasanatmetal.hu 510(k) Statement of Summary

More information